Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Single-arm Phase II Trial of Sotorasib Plus Lenvatinib, As Second-line Treatment in Patients with KRASG12C-mutant, Metastatic NSCLC

NCT06068153 is registered in ClinicalTrials.gov with ETOP IBCSG Partners Foundation as lead sponsor.

NCT NCT06068153
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06068153 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Single-arm Phase II Trial of Sotorasib Plus Lenvatinib, As Second-line Treatment in Patients with KRASG12C-mutant, Metastatic NSCLC
Lead sponsor
ETOP IBCSG Partners Foundation
Phase
Phase 2
Overall status
Withdrawn
Start date
March 31, 2025
Completion date
December 30, 2026
Enrollment
0 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

kras g12c, metastatic non small cell lung cancer